

Hepatocyte Growth Factor - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HFCC9D28EDA1EN.html>

Date: April 2020

Pages: 80

Price: US\$ 3,500.00 (Single User License)

ID: HFCC9D28EDA1EN

Abstracts

Hepatocyte Growth Factor - Pipeline Review, H1 2020

SUMMARY

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules. The latest report Hepatocyte Growth Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 4 and 3 respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Respiratory which include indications Amyotrophic Lateral Sclerosis, Colorectal Cancer, Critical Limb Ischemia, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Advanced

Malignancy, Alzheimer's Disease, Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lung Injury, Lymphedema, Lymphoma, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuromuscular Disorders, Non-Small Cell Lung Cancer, Parkinson's Disease, Peripheral Artery Occlusive Disease (PAOD), Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar and Thromboangiitis obliterans (Buerger disease).

Furthermore, this report also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all

their major and minor projects

The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies

Involved in Therapeutics Development

AnGes Inc

Athira Pharma Inc

Beijing SH Bio-Tech Corp

Helixmith Co Ltd

i2 Pharmaceuticals Inc

Kringle Pharma Inc

Minerva Biotechnologies Corp

Molecular Partners AG

Yichang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles

Ad-HGF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bepermingene perplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donapermingene seltoplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to activate HGF for Lung Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDX-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones

Featured News & Press Releases

Feb 04, 2020: AnGes, Inc. initiated Phase 2b study in the U.S. in patients with lower limb ischemic ulcers

Dec 27, 2019: Molecular Partners receives orphan drug designation for MP0250 for multiple myeloma

Dec 20, 2019: Genopis, plasmid DNA manufacturer in San Diego, to Launch GMP contract manufacturing business

Dec 12, 2019: Molecular Partners provides update on its Multiple Myeloma drug candidate MP-0250 at R&D Day

Dec 09, 2019: Athira Pharma presents positive data for NDX-1017 in Alzheimer's patients at 2019 clinical trials on Alzheimer's disease (CTAD) conference

Dec 07, 2019: Molecular Partners presents updated results of MP0250 in patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting

Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference

Oct 07, 2019: Helixmith shows long-term safety and efficacy of VM202 for painful DPN patients in DPN phase 3-1b extension study

Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients

Sep 23, 2019: Helixmith: Topline results of DPN Phase III study

Sep 04, 2019: Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy product

Aug 02, 2019: Helixmith unveils results for neuromuscular disease treatment

Jul 16, 2019: Athira Pharma presents preliminary results from phase 1 trial of NDX-1017 at Alzheimer's Association International Conference 2019 (AAIC)

May 27, 2019: Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment

May 01, 2019: Athira Pharma announces appointment of Dr. Hans J. Moebius as chief medical officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by AnGes Inc, H1 2020

Pipeline by Athira Pharma Inc, H1 2020

Pipeline by Beijing SH Bio-Tech Corp, H1 2020

Pipeline by Helixmith Co Ltd, H1 2020

Pipeline by i2 Pharmaceuticals Inc, H1 2020

Pipeline by Kringle Pharma Inc, H1 2020

Pipeline by Minerva Biotechnologies Corp, H1 2020

Pipeline by Molecular Partners AG, H1 2020

Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020

Pipeline by Yooyoung Pharm Co Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AnGes Inc
Athira Pharma Inc
Beijing SH Bio-Tech Corp
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd

I would like to order

Product name: Hepatocyte Growth Factor - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HFCC9D28EDA1EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HFCC9D28EDA1EN.html>